The mission of the Clinical Trials Support Resource is to serve the patients, faculty, and staff of the University of Texas M.D. Anderson Cancer Center by facilitating the approval and performance of clinical research of the highest quality in an ethical and cost-effective fashion. The Clinical Trials Support Resource is supported by the Office of Protocol Research (OPR) staff and is directed by the Associate Vice President for Clinical and Translational Research and an Administrative Director and is divided into four specialized areas: Protocol Approval and Regulatory Affairs, Office of Clinical Research Quality Assurance, Protocol Data Management System, and Research Finance. The Protocol Approval and Regulatory Affairs area supports the protocol approval process for the clinical Research Committee; the Psychosocial, Behavioral, and Health Services Research Committee; and the Surveillance Committee (Institutional Review Board) to ensure that scientific and patient protection issues are adequately addressed and that the protocols are approved at the institutional level before they are submitted to the NCI for approval. The Office of Clinical Research Quality Assurance monitors the quality of research data, serves as resource in improving data management, and provides an institutional mechanism for managing issues related to research deficiencies or problems. This office works closely with the Protocol Approval and Regulatory Affairs staff to ensure that the NCI stipulations are being met and that the requirement for the PRMS designation in protocol accrual is monitored is fulfilled. The Protocol Data Management System staff supports a comprehensive database developed for clinical research personnel at M.D. Anderson Cancer Center. It provides on-line patient registration for all clinical research protocols and is primarily responsible for tracking submission, patient accrual, adverse events, annual reviews, activations, and terminations for all clinical research protocols. It too plays a critical role in the PMRS process. The Research Finance staff is responsible for overseeing the protocol activity in the Clinical Research Unit and utilizing a cost model to prospectively project the cost and charge of protocols. Although each area is involved with special projects, the primary focus of the Clinical Trials Support Resource is to ensure that the principal investigators are in compliance with federal and institutional regulations, to maintain protocol-related information for the institution, to provide protocol management services to investigators, and to refine the financial system surrounding clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-26
Application #
6481857
Study Section
Project Start
2001-08-01
Project End
2002-06-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
$254,104
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Murray, Thomas A; Yuan, Ying; Thall, Peter F et al. (2018) A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics 74:1095-1103
Sun, Lin-Lin; Yang, Ri-Yao; Li, Chia-Wei et al. (2018) Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res 8:1307-1316
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Veletic, Ivo; Manshouri, Taghi; Newberry, Kate J et al. (2018) Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. Br J Haematol :
El Fakih, Riad; Jabbour, Elias; Ravandi, Farhad et al. (2018) Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. Am J Hematol 93:286-295
Sankhala, Kamalesh; Takimoto, Chris H; Mita, Alain C et al. (2018) Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Invest New Drugs :
Shen, Weining; Ning, Jing; Yuan, Ying et al. (2018) Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics 74:239-248
Wu, Shaofang; Wang, Shuzhen; Gao, Feng et al. (2018) Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma. Neuro Oncol 20:78-91
Romano, Gabriele; Chen, Pei-Ling; Song, Ping et al. (2018) A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov 8:556-567
Dray, Beth K; Raveendran, Muthuswamy; Harris, R Alan et al. (2018) Mismatch repair gene mutations lead to lynch syndrome colorectal cancer in rhesus macaques. Genes Cancer 9:142-152

Showing the most recent 10 out of 12418 publications